SOURCE: StockCall


October 11, 2010 08:51 ET

Research on Merck & Co. and AstraZeneca - The Clock is Ticking

JOHANNESBURG, SOUTH AFRICA--(Marketwire - October 11, 2010) - offers investors comprehensive research on the drug manufacturers industry and has completed analytical research on Merck & Co. Inc. (NYSE: MRK) and AstraZeneca plc (NYSE: AZN). Register with us today at to have free access to these researches. 

Companies in the Drug manufacturing business are facing a serious threat to business now and over the next few years as exclusive patents for their products expire. Following patent expiry generic companies are legally allowed to create generic alternatives which not only create competition but generally offer a cheaper option to the original branded drug. Register now at to have free access to our reports on the drug manufacturers industry. is an online platform where investors doing their due-diligence on the drug manufacturers industry can have easy and free access to our analyst research and opinions on Merck & Co. Inc. and AstraZeneca plc; investors and shareholders of these companies can simply register for a complimentary membership at

With popular drugs such as Lipitor, Cozaar/Hyzaar, Arimidex, and Hycamtin set to soon expire, major drug manufacturers are going to have a tougher road ahead of them. Some companies have been known to pay other companies to not produce generic alternatives, while others move forward and invest in research and development to try and find the next big cure, or simply the next bestseller. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

Major players in the industry such as Merck & Co. Inc. and AstraZeneca plc are investing heavily into finding treatments for various forms of cancer, hepatitis C, Alzheimer and arthritis to name a few. In order to keep profits up, drug manufacturers are hoping that they will be able to bring new treatments to market in the near future knowing that regulations and competition is getting tougher. Investors can register for free to access the research reports on Merck & Co. Inc. and AstraZeneca plc at or

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information